Uncategorized
Inotek completes recruitment for phase 3 trial of trabodenoson
Inotek Pharmaceuticals completed active recruitment for MATrX-1, the first pivotal phase 3 trial of trabodenoson for the treatment of glaucoma.Topline data are expected to be released in December, according to a press release.